Author of

• 20169

  +

  P2.05 - Early Stage NSCLC (ID 706)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Early Stage NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23345

    +

    P2.05-002 - A Pilot Study on the Safety and the Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumor (ID 8164)

    09:30 - 09:30  |  Author(s): N. Ueki
    • Abstract

    Background:
    Stereotactic body radiation therapy (SBRT) is an important treatment option of solitary lung tumor. A total dose of 48Gy in 4 fractions (fr.) at the isocenter has been most widely used in Japan, however, local recurrences were observed in the long term follow-up study in 10% or more. To improve local control rates after SBRT, the most promising treatment strategy will be dose escalation. Then we started a pilot study to evaluate the safety and efficacy of dose escalation in SBRT for peripheral lung tumor.
    
    Method:
    We designed to enroll 35 patients treated with SBRT prospectively. The primary endpoint was the incidence of adverse effects within 1 year after SBRT. Adverse effects were evaluated by the CTCAE ver. 4.0. In this study, the prescription dose was 70 Gy in 4 fr. at the isocenter, covering the planning target volume (PTV) surface with 70%-isodose line.
    
    Result:
    A total of 35 patients were enrolled between October 2014 and January 2016. Patient and tumor characteristics are shown in the table. The median follow-up duration was 21.0 months (range, 4.2–31.2 months). Grade 2 radiation pneumonitis and Grade 2 rib fractures were observed in 5 patients (14.3%) and 5 (14.3%), respectively. There was no other Grade 3 or more adverse effect. Local recurrence was observed in one patient, and it was a recurrence of metastatic lung tumor. Out of 32 primary lung cancers, no local recurrence was observed.

    Patient and tumor characteristics

    Characteristics			Number	%
    Patients			35	100
    Age (y)
    	Median (range)		77 (58-92)
    Gender
    	Male		23	66
    	Female		12	34
    ECOG performance status
    	0		10	28
    	1		22	63
    	2		3	9
    Disease
    	Primary lung cancer		32	91
    	Histology
    		Adenocarcinoma	10	28
    		Squamous cell carcinoma	3	9
    		Clinically diagnosed	19	54
    	T-stage
    		T1a	15	43
    		T1b	11	31
    		T2a	6	17
    	Lung metastasis		3	9
    Target location
    	Upper/middle		26	74
    	Lower		9	26

    
    
    Conclusion:
    We confirmed that the treatment method is feasible in the acute and subacute phases. It was also suggested that this method can obtain excellent local control rate.